Pluristem Therapeutics | Hadassah International

Pluristem Stem Cell therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA to Treat Acute Radiation Syndrome

Pluristem Therapeutics has announced that its new cell therapy to treat acute radiation syndrome (PLX-R18), based on the pioneering studies performed within the laboratory of Prof. Raphael Gorodetsky at the…

Facebook

Twitter

Cancer Research

Hadassah and Pluristem Report Stem Cells Improve Outcome of Bone Marrow Transplant

Placenta-based Cell Therapy

Leading Developer of Cell Therapy To Collaborate with Hadassah for Safer Transplants

Placenta-based Cell Therapy

Hadassah International

Pluristem Stem Cell therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA to Treat Acute Radiation Syndrome

Pluristem Stem Cell therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA to Treat Acute Radiation Syndrome

Hadassah and Pluristem Report Stem Cells Improve Outcome of Bone Marrow Transplant

Leading Developer of Cell Therapy To Collaborate with Hadassah for Safer Transplants

Placental Cells Mitigate Radiation-Induced Complications in Mice, Hadassah Researchers Reveal